Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Incyte Corporation is a biopharmaceutical company. The Company discovers, develops, and commercializes proprietary small molecule drugs, primarily used in oncology.
Website: incyte.com



Growth: Good revenue growth rate 27.8%, there is acceleration compared to average historical growth rates 14.9%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -8.8%

Profitability: LTM EBITDA margin is positive, +31.4%. On average the margin is decreasing unsteadily. In the last quarter the company did not beat the estimated EPS, -50.7%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 7.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 90.6% higher than minimum and 9.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.0x by EV / Sales multiple , the company can be 30.1% undervalued

Insiders: For the last 3 months insiders sold company shares on $5.2 mln (-0.028% of cap.)

Key Financials (Download financials)

Ticker: INCY
Share price, USD:  (+5.7%)97.54
year average price 92.34  


year start price 67.42 2025-06-04

min close price 67.24 2025-06-05

max close price 108.26 2025-11-12

current price 97.54 2026-06-04
Common stocks: 197 441 000

Dividend Yield:  0.0%
FCF Yield LTM: 7.4%
EV / LTM EBITDA: 9.7x
EV / EBITDA annualized: 10.4x
Last revenue growth (y/y):  +27.8%
Last growth of EBITDA (y/y):  +10.7%
Historical revenue growth:  +14.9%
Historical growth of EBITDA:  +44.9%
EV / Sales: 3.1x
Margin (EBITDA LTM / Revenue): 31.4%
Fundamental value created in LTM:
Market Cap ($m): 19 258
Net Debt ($m): -3 546
EV (Enterprise Value): 15 712
Price to Book: 3.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2026-01-26zacks.com

Here's Why Incyte (INCY) is a Strong Momentum Stock

2026-01-23zacks.com

Why Incyte (INCY) is a Top Value Stock for the Long-Term

2026-01-22seekingalpha.com

What Investors Should Know Before Buying Incyte

2026-01-16seekingalpha.com

Incyte: Buy For The Turnaround, Stay For The Pipeline

2026-01-16seekingalpha.com

Incyte's Pipeline Potential Signals Massive Upside For Investors

2026-01-13youtube.com

Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

2025-12-22zacks.com

Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?

2025-12-22businesswire.com

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

2025-12-22businesswire.com

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-30 2024-04-30 2023-10-31 2023-08-01 2023-05-02 2022-11-01
acceptedDate 2025-10-28 16:03:42 2025-07-29 16:01:59 2025-02-10 16:01:48 2024-10-29 16:02:00 2024-07-30 16:10:17 2024-04-30 16:02:03 2024-02-16 16:04:47 2023-10-31 16:02:05 2023-08-01 16:02:22 2023-05-02 16:03:00 2023-02-07 16:02:05 2022-11-01 16:06:15 2022-02-08 16:05:11 2021-02-09 16:05:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 366M 1 216M 4 241M 1 138M 1 044M 881M 3 696M 919M 955M 809M 3 395M 823M 2 986M 2 667M
costOfRevenue 99M 96M 378M 86M 93M 61M 315M 60M 68M 57M 253M 55M 187M 162M
grossProfit 1 267M 1 120M 3 864M 1 052M 951M 820M 3 380M 859M 886M 752M 3 141M 769M 2 799M 2 505M
grossProfitRatio 0.928 0.921 0.924 0.911 0.931 0.935 0.928 0.93 0.934
researchAndDevelopmentExpenses 507M 478M 2 607M 573M 1 138M 429M 1 628M 376M 401M 407M 1 586M 384M 1 458M 2 216M
generalAndAdministrativeExpenses 329M 0 0 309M 286M 300M 0 268M 284M 316M 0 267M 0 0
sellingAndMarketingExpenses 0 0 0 0 4M 0 0 -7000 0 6000 0 0 0 0
sellingGeneralAndAdministrativeExpenses 329M 331M 1 177M 309M 290M 300M 1 101M 268M 284M 316M 956M 267M 703M 517M
otherExpenses -12M 0 0 23M 893 000 0 0 627 000 8M -1M 0 2M 0 13M
operatingExpenses 823M 809M 3 783M 906M 1 428M 729M 2 729M 645M 684M 721M 2 542M 652M 2 161M 2 745M
costAndExpenses 922M 905M 4 161M 992M 1 521M 790M 3 044M 705M 752M 778M 2 795M 707M 2 349M 2 907M
interestIncome 27M 25M 129M 24M 50M 45M 0 46M 43M 33M 0 0 0 0
interestExpense 592 000 594 000 2M 774 000 657 000 430 000 3M 623 000 655 000 469 000 3M 641 000 2M 2M
depreciationAndAmortization 24M 23M 89M 23M 22M 22M 83M 46M 20M -27M 68M 28M 58M 52M
ebitda 507M 582M 408M 180M -367M 158M 919M 261M 265M 64M 600M 166M 630M -178M
ebitdaratio 0.371 0.478 0.158 -0.436 0.18 0.284 0.278 0.079 0.202
operatingIncome 444M 311M 80M 146M -477M 92M 652M 215M 194M 90M 600M 138M 638M -240M
operatingIncomeRatio 0.325 0.256 0.128 -0.457 0.104 0.234 0.203 0.112 0.168
totalOtherIncomeExpensesNet 39M 247M 236M 10M 88M 100M 182M -26M 33M -39M -70M 10M -67M 8M
incomeBeforeTax 482M 558M 317M 157M -390M 236M 834M 234M 278M 52M 529M 149M 570M -232M
incomeBeforeTaxRatio 0.353 0.459 0.138 -0.373 0.268 0.254 0.291 0.064 0.18
incomeTaxExpense 58M 153M 284M 50M 55M 67M 237M 63M 74M 30M 188M 36M -378M 63M
netIncome 424M 405M 33M 106M -445M 170M 598M 171M 204M 22M 341M 113M 949M -296M
netIncomeRatio 0.311 0.333 0.094 -0.426 0.192 0.186 0.213 0.027 0.137
eps 2.17 2.09 0.16 0.55 -2.04 0.76 2.67 0.76 0.91 0.1 1.53 0.51 4.3 -1.36
epsdiluted 2.11 2.04 0.54 -2.04 0.75 0.76 0.9 0.1 0.5
weightedAverageShsOut 196M 194M 207M 193M 218M 224M 224M 224M 223M 223M 222M 222M 220M 218M
weightedAverageShsOutDil 201M 199M 211M 196M 218M 227M 226M 226M 226M 226M 224M 224M 222M 218M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-16 2023-02-07 2022-02-08 2021-02-09
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 126M -3M -3M -2M -2M
ebit 319M 837M 532M 572M -230M
nonOperatingIncomeExcludingInterest -239M -185M 68M 65M -10M
netIncomeFromContinuingOperations 33M 598M 341M 949M -296M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 33M 598M 341M 949M -296M
epsDiluted 0.15 2.65 1.52 4.27 -1.36

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-30 2024-04-30 2023-10-31 2023-08-01 2023-05-02 2022-11-01
acceptedDate 2025-10-28 16:03:42 2025-07-29 16:01:59 2025-02-10 16:01:48 2024-10-29 16:02:00 2024-07-30 16:10:17 2024-04-30 16:02:03 2024-02-16 16:04:47 2023-10-31 16:02:05 2023-08-01 16:02:22 2023-05-02 16:03:00 2023-02-07 16:02:05 2022-11-01 16:06:15 2022-02-08 16:05:11 2021-02-09 16:05:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 2 455M 1 955M 1 688M 1 304M 987M 3 346M 3 213M 3 227M 3 131M 2 821M 2 951M 2 691M 2 057M 1 513M
shortTermInvestments 475M 467M 470M 471M 532M 504M 443M 289M 292M 292M 288M 287M 291M 288M
cashAndShortTermInvestments 2 930M 2 422M 2 158M 1 775M 1 519M 3 851M 3 656M 3 516M 3 423M 3 113M 3 239M 2 977M 2 348M 1 801M
netReceivables 896M 843M 853M 758M 739M 746M 744M 657M 638M 624M 645M 618M 616M 482M
inventory 450M 83M 59M 70M 101M 64M 63M 199M 36M 158M 42M 46M 28M 16M
otherCurrentAssets 0 296M 169M 205M 208M 189M 183M 254M 167M 217M 167M 180M 0 0
totalCurrentAssets 4 276M 3 644M 3 239M 2 809M 2 567M 4 849M 4 645M 4 627M 4 264M 4 111M 4 093M 3 821M 3 119M 2 360M
propertyPlantEquipmentNet 827M 828M 794M 798M 788M 746M 777M 758M 775M 768M 766M 742M 751M 588M
goodwill 156M 156M 156M 156M 156M 156M 156M 156M 156M 156M 156M 156M 156M 156M
intangibleAssets 119M 126M 114M 120M 114M 118M 124M 129M 135M 141M 129M 135M 151M 172M
goodwillAndIntangibleAssets 275M 282M 269M 276M 269M 273M 279M 285M 291M 296M 285M 290M 306M 328M
longTermInvestments 22M 13M 19M 28M 31M 288M 188M 154M 170M 128M 134M 149M 221M 222M
taxAssets 528M 652M 762M 762M 730M 667M 632M 564M 533M 495M 458M 427M 468M 2M
otherNonCurrentAssets -22M 403M 361M 340M 277M 313M 261M 0 175M 0 106M 81M 68M 61M
totalNonCurrentAssets 1 630M 2 178M 2 205M 2 204M 2 095M 2 287M 2 137M 1 761M 1 944M 1 687M 1 748M 1 689M 1 815M 1 201M
otherAssets 425M 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 6 330M 5 821M 5 444M 5 012M 4 662M 7 136M 6 782M 6 388M 6 208M 5 798M 5 841M 5 510M 4 933M 3 561M
accountPayables 1 460M 241M 197M 179M 148M 164M 110M 1 218M 156M 56M 278M 163M 172M 99M
shortTermDebt 10M 11M 0 8M 9M 8M 0 3M 10M 3M 0 12M 0 0
taxPayables 0 0 24M 33M 32M 127M 42M 0 0 0 7M 0 0 0
deferredRevenue 0 0 0 0 0 1 121M 0 -985M 829M 0 0 0 0 0
otherCurrentLiabilities -126M 1 022M 725M 1 282M 1 148M 103M 545M 982M 124M 1 025M 436M 832M 328M 260M
totalCurrentLiabilities 1 339M 1 279M 1 642M 1 502M 1 337M 1 396M 1 240M 1 218M 1 119M 1 084M 1 157M 1 007M 854M 631M
longTermDebt 31M 32M 0 28M 29M 29M 0 32M 29M 33M 0 30M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 310M 340M 321M 311M 299M 316M 323M 207M 319M 218M 284M 102M 277M 286M
totalNonCurrentLiabilities 340M 372M 355M 340M 328M 345M 352M 239M 349M 251M 314M 277M 309M 318M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 31M 42M 44M 37M 38M 37M 38M 32M 40M 33M 41M 42M 45M 48M
totalLiabilities 1 679M 1 650M 1 997M 1 841M 1 665M 1 741M 1 592M 1 457M 1 468M 1 335M 1 471M 1 284M 1 163M 950M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 196 000 194 000 193 000 192 000 191 000 224 000 224 000 224 000 223 000 223 000 223 000 222 000 221 000 219 000
retainedEarnings -86M -510M -1 073M -1 274M -1 380M 330M 160M -41M -212M -416M -437M -466M -778M -1 726M
accumulatedOtherComprehensiveIncomeLoss 15M 13M -13M 16M -5M -6M 13M 23M 27M 21M 15M -29M -19M -15M
othertotalStockholdersEquity 4 722M 4 667M 4 429M 4 383M 5 070M 4 949M 4 926M 4 857M 4 721M
totalStockholdersEquity 4 651M 4 171M 3 448M 3 171M 2 997M 5 394M 5 190M 4 931M 4 741M 4 463M 4 370M 4 227M 3 770M 2 611M
totalEquity 4 651M 4 171M 3 448M 3 171M 2 997M 5 394M 5 190M 4 931M 4 741M 4 463M 4 370M 4 227M 3 770M 2 611M
totalLiabilitiesAndStockholdersEquity 6 330M 5 821M 5 012M 4 662M 7 136M 6 388M 6 208M 5 798M 5 510M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 6 330M 5 821M 5 444M 5 012M 4 662M 7 136M 6 782M 6 388M 6 208M 5 798M 5 841M 5 510M 4 933M 3 561M
totalInvestments 497M 480M 489M 498M 563M 792M 630M 443M 463M 420M 421M 436M 512M 511M
totalDebt 41M 42M 44M 37M 38M 37M 38M 32M 40M 33M 41M 42M 45M 48M
netDebt -2 414M -1 913M -1 644M -1 268M -950M -3 309M -3 175M -3 195M -3 091M -2 788M -2 910M -2 649M -2 013M -1 465M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-16 2023-02-07 2022-02-08 2021-02-09
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 853M 744M 645M 616M 482M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 126M 60M
totalPayables 221M 152M 285M 172M 99M
otherPayables 24M 42M 7M 0 0
accruedExpenses 686M 534M 425M 341M 257M
capitalLeaseObligationsCurrent 10M 9M 11M 13M 15M
capitalLeaseObligationsNonCurrent 34M 29M 30M 32M 33M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 4 533M 5 016M 4 792M 4 567M 4 353M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY INCY
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169 879 169
fillingDate 2025-10-28 2025-07-29 2024-10-29 2024-07-30 2024-04-30 2023-10-31 2023-08-01 2023-05-02 2022-11-01
acceptedDate 2025-10-28 16:03:42 2025-07-29 16:01:59 2025-02-10 16:01:48 2024-10-29 16:02:00 2024-07-30 16:10:17 2024-04-30 16:02:03 2024-02-16 16:04:47 2023-10-31 16:02:05 2023-08-01 16:02:22 2023-05-02 16:03:00 2023-02-07 16:02:05 2022-11-01 16:06:15 2022-02-08 16:05:11 2021-02-09 16:05:42
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 424M 405M 33M 106M -445M 170M 598M 171M 204M 22M 341M 113M 949M -296M
depreciationAndAmortization 24M 23M 89M 23M 22M 22M 83M 21M 20M 19M 68M 17M 58M 52M
deferredIncomeTax 124M 117M -86M -34M -17M -34M -159M -31M -40M -22M 57M 8M -466M -350 000
stockBasedCompensation 62M 65M 266M 78M 57M 60M 216M 48M 55M 53M 188M 45M 183M 178M
changeInWorkingCapital 570M -583M 138M 109M -153M 99M -249M -91M 102M -187M 199M 128M -15M -72M
accountsReceivables -53M -20M -112M -19M 6M -2M -99M -19M -14M 21M -29M 65M -134M -173M
inventory -6M -20M -128M -8M -28M -57M -170M -24M -20M -33M -68M -11M -21M -19M
accountsPayables -44M 20M 88M 31M -16M 55M -168M -16M 100M -222M 105M -32M 73M 15M
otherWorkingCapital 673M -563M 289M 106M -116M 104M 188M -32M 37M 234M 189M 106M 67M 106M
otherNonCashItems -644M 18M -105M 29M 99M 2M 8M 29M -34M 9M 117M -15M 40M 14M
netCashProvidedByOperatingActivities 559M 45M 335M 311M -576M 219M 496M 148M 307M -106M 970M 296M 749M -125M
investmentsInPropertyPlantAndEquipment -15M -19M -86M 0 -56M -10M -47M -11M -7M -27M -78M -28M -181M -187M
acquisitionsNet 0 0 0 0 0 0 47M 11M 7M 15M 709 000 0 181M 187M
purchasesOfInvestments -116M -56M -258M -25M -38M -166M -466M -80M -97M -55M -80M -15M -269M -612M
salesMaturitiesOfInvestments 108M 56M 516M 81M 308M 102M 306M 74M 97M 53M 79M 14M 242M 531M
otherInvestingActivites -25M 0 -18M 268M -64M -11M -7M -15M -28M
netCashUsedForInvestingActivites -47M -19M 38M 214M -73M -17M -7M -29M -28M
debtRepayment -1M -1M -979 000 -911 000 -871 000 -885 000 -836 000 -802 000 -738 000
commonStockIssued 0 15M 1M 0 477 000 -48 000 0 14M 0
commonStockRepurchased 0 -19M -2 005M -103 000 -2 005M -6M 0 -25M 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -12M -6M -31M 24M -12M 13M 14M -9M -14M
netCashUsedProvidedByFinancingActivities -13M -11M -32M -1 997M -12M -37M 13M 4M -14M
effectOfForexChangesOnCash 841 000 -1M 3M 128 000 13 000 -676 000 -7M 3M -2M -199 000 3M 2M -4M 3M
netChangeInCash 500M 13M -1 526M 319M -2 359M 133M 262M 96M 310M -130M 894M 255M 544M -319M
cashAtEndOfPeriod 2 457M 1 957M 1 689M 1 306M 987M 3 348M 3 215M 3 229M 3 133M 2 823M 2 953M 2 692M 2 059M 1 515M
cashAtBeginningOfPeriod 1 957M 1 943M 3 215M 987M 3 346M 3 215M 2 953M 3 133M 2 823M 2 953M 2 059M 2 437M 1 515M 1 834M
operatingCashFlow 559M 45M 335M 311M -576M 219M 496M 148M 307M -106M 970M 296M 749M -125M
capitalExpenditure -15M -19M -86M -18M -56M -10M -47M -11M -7M -27M -78M -28M -181M -187M
freeCashFlow 545M 26M 249M 293M -631M 209M 449M 137M 299M -133M 892M 269M 568M -312M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-10 2024-02-16 2023-02-07 2022-02-08 2021-02-09
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -14M -47M -709 000 -181M -187M
netCashProvidedByInvestingActivities 158M -208M -79M -208M -269M
netDebtIssuance -4M -3M -3M -2M -836 000
longTermNetDebtIssuance -4M -3M -3M -2M -836 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -2 005M 36M 61M 59M 110M
netCommonStockIssuance -2 005M 36M 61M 59M 110M
commonStockIssuance 0 36M 61M 59M 110M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -13M -53M -59M -50M -38M
netCashProvidedByFinancingActivities -2 022M -20M -794 000 6M 72M
incomeTaxesPaid 373M 378M 136M 68M 71M
interestPaid 0 0 0 396 000 0

Earning call transcript

2025 q3
2025-10-28 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-10 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-30 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-13 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-04-29 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2026-04-28 11:00 ET
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
2026-04-28 11:00 ET
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-21 14:00 ET
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-04-09 ET
Incyte to Report First Quarter Financial Results
2026-04-02 ET
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
2026-03-28 ET
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-25 ET
Incyte Announces Executive Leadership Appointments
2026-03-20 ET
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-06 ET
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
2026-02-27 ET
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
2026-02-17 13:00 ET
Incyte to Present at Upcoming Investor Conferences
2026-02-10 12:00 ET
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-30 ET
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
2026-01-27 ET
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
2026-01-05 ET
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
2025-12-22 ET
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-22 ET
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
2025-12-18 ET
Incyte to Present at Upcoming Investor Conference
2025-12-17 ET
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-12 ET
Incyte Announces Change to its Board of Directors
2025-12-08 ET
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
2025-12-07 ET
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
2025-12-07 ET
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
2025-12-03 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 ET
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
2025-12-01 ET
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
2025-11-19 ET
Incyte to Present at Upcoming Investor Conferences
2025-11-17 ET
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
2025-11-06 ET
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
2025-11-04 ET
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
2025-11-03 ET
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
2025-10-30 ET
Incyte to Present at Upcoming Investor Conferences
2025-10-28 11:00 ET
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-10-27 ET
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
2025-10-25 ET
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
2025-10-24 ET
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
2025-10-19 ET
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
2025-10-12 ET
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
2025-10-08 ET
Incyte to Report Third Quarter Financial Results
2025-09-24 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-09-22 ET
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
2025-09-18 ET
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
2025-09-17 ET
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
2025-09-10 ET
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
2025-09-03 ET
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
2025-08-27 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 ET
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
2025-08-19 ET
Incyte to Present at Upcoming Investor Conferences
2025-08-04 ET
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
2025-07-31 ET
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
2025-07-29 ET
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2025-07-24 ET
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
2025-07-10 ET
Incyte to Report Second Quarter Financial Results
2025-07-02 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-06-26 ET
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
2025-06-20 ET
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
2025-06-18 ET
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
2025-06-15 ET
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
2025-06-12 ET
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
2025-06-12 ET
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
2025-06-06 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-03 ET
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
2025-05-27 ET
Incyte to Present at Upcoming Investor Conference
2025-05-15 ET
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
2025-05-07 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-01 ET
Incyte to Present at Upcoming Investor Conference
2025-04-29 ET
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2025-04-25 ET
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
2025-04-23 ET
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-04-10 ET
Incyte to Report First Quarter Financial Results
2025-04-07 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-17 ET
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
2025-03-08 ET
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
2025-03-08 ET
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
2025-03-07 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-28 ET
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
2025-02-20 ET
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
2025-02-18 ET
Incyte to Present at Upcoming Investor Conferences
2025-02-10 ET
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
2025-02-07 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-21 ET
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
2025-01-13 ET
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-08 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-17 ET
Incyte to Present at Upcoming Investor Conference
2024-12-10 ET
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
2024-12-07 ET
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
2024-12-06 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-26 ET
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
2024-11-25 ET
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
2024-11-18 ET
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
2024-11-14 ET
Incyte to Present at Upcoming Investor Conference
2024-11-07 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-30 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2024-10-29 11:00 ET
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2024-10-24 18:03 ET
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
2024-10-10 13:15 ET
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
2024-10-08 12:00 ET
Incyte to Report Third Quarter Financial Results
2024-10-08 03:08 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-03 20:30 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-09-25 11:00 ET
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
2024-09-18 21:15 ET
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
2024-09-14 16:45 ET
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
2024-09-14 14:30 ET
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
2024-09-09 20:30 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-13 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2024-08-07 21:00 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-07-30 11:00 ET
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2024-07-09 12:00 ET
Incyte to Report Second Quarter Financial Results
2024-07-08 20:30 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-13 12:00 ET
Incyte Announces Final Results of Tender Offer
2024-06-11 12:00 ET
Incyte Announces Preliminary Results of Tender Offer
2024-06-07 20:30 ET
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-30 20:05 ET
Incyte Completes Acquisition of Escient Pharmaceuticals
2024-05-21 17:15 ET
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
2024-05-21 12:00 ET
Incyte to Present at Upcoming Investor Conference
2024-05-14 21:00 ET
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
2024-05-13 11:00 ET
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
2024-05-02 12:00 ET
Incyte to Present at Upcoming Investor Conference
2024-04-30 11:00 ET
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2024-04-23 11:00 ET
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
2024-04-11 12:00 ET
Incyte to Report First Quarter Financial Results
2024-04-01 12:30 ET
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
2024-03-29 20:30 ET
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-10 20:05 ET
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
2024-03-10 20:05 ET
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
2024-03-04 13:00 ET
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2024-02-29 15:19 ET
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
2024-02-29 12:30 ET
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
2024-02-27 21:08 ET
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
2024-02-15 13:00 ET
Incyte to Present at Upcoming Investor Conference
2024-02-13 12:00 ET
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
2024-01-23 13:00 ET
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
2024-01-08 13:30 ET
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 13:00 ET
Incyte to Present at Upcoming Investor Conferences
2023-11-02 13:00 ET
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
2023-10-31 11:00 ET
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-10-27 12:00 ET
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
2023-10-18 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2023-10-16 12:00 ET
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
2023-10-13 14:30 ET
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
2023-10-13 12:00 ET
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
2023-10-11 14:30 ET
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
2023-10-11 13:15 ET
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
2023-10-11 12:15 ET
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
2023-10-10 20:45 ET
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
2023-10-10 12:00 ET
Incyte to Report Third Quarter Financial Results
2023-09-29 17:43 ET
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
2023-08-22 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2023-08-01 11:00 ET
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-07-31 20:01 ET
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
2023-07-11 20:05 ET
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
2023-07-11 12:00 ET
Incyte to Report Second Quarter Financial Results
2023-07-05 10:12 ET
MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
2023-06-27 20:00 ET
LYMPHOMA THERAPY NOW APPROVED FOR AUSTRALIAN PATIENTS With Diffuse Large B-cell Lymphoma
2023-05-25 21:01 ET
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
2023-05-23 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2023-05-08 12:30 ET
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
2023-05-02 11:00 ET
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-05-01 19:00 ET
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
2023-04-20 14:21 ET
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
2023-04-18 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2023-04-11 12:00 ET
Incyte to Report First Quarter Financial Results
2023-03-27 06:00 ET
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
2023-03-24 00:55 ET
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
2023-03-22 17:14 ET
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
2023-03-18 19:40 ET
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
2023-03-18 14:40 ET
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
2023-03-14 22:30 ET
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
2023-03-07 11:30 ET
Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline
2023-03-06 17:23 ET
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
2023-03-03 21:35 ET
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
2023-02-24 12:07 ET
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
2023-02-16 13:00 ET
Incyte to Present at Upcoming Investor Conference
2023-02-10 13:20 ET
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
2023-02-07 12:00 ET
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
2023-01-24 13:00 ET
Incyte to Present at Upcoming Investor Conference
2023-01-17 13:00 ET
Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
2022-12-15 13:00 ET
Incyte to Present at Upcoming Investor Conferences
2022-12-11 20:00 ET
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
2022-12-10 20:00 ET
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
2022-12-02 13:30 ET
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
2022-11-17 13:00 ET
Incyte to Present at Upcoming Investor Conferences
2022-11-07 13:00 ET
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
2022-11-03 14:24 ET
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
2022-11-01 11:00 ET
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2022-10-19 22:17 ET
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
2022-10-11 12:00 ET
Incyte to Report Third Quarter Financial Results
2022-10-06 22:12 ET
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
2022-10-04 12:00 ET
Incyte Names New Member to Its Board of Directors
2022-10-03 10:00 ET
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
2022-09-15 13:00 ET
New treatment for rare cancer cholangiocarcinoma approved in Australia
2022-08-26 14:00 ET
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
2022-08-24 12:00 ET
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
2022-08-23 12:00 ET
Incyte to Present at Upcoming Investor Conference
2022-08-02 11:00 ET
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2022-07-19 01:08 ET
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
2022-07-12 12:00 ET
Incyte to Report Second Quarter Financial Results
2022-06-14 01:50 ET
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
2022-05-26 10:00 ET
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
2022-05-24 12:00 ET
Incyte to Present at Upcoming Investor Conference
2022-05-20 12:11 ET
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
2022-05-11 10:45 ET
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
2022-05-05 05:20 ET
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
2022-05-04 20:15 ET
Incyte to Present at Upcoming Investor Conference
2022-05-03 11:00 ET
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2022-04-29 20:16 ET
Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights
2022-04-28 20:05 ET
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
2022-04-22 13:40 ET
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
2022-04-12 12:00 ET
Incyte to Report First Quarter Financial Results
2022-03-26 15:20 ET
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
2022-03-26 14:40 ET
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
2022-03-25 12:30 ET
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
2022-03-18 13:56 ET
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
2022-03-14 12:00 ET
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
2022-02-15 13:00 ET
Incyte to Present at Upcoming Investor Conference
2022-02-08 12:00 ET
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
2022-02-03 13:00 ET
Incyte to Present at Upcoming Investor Conference
2022-01-28 13:00 ET
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
2022-01-25 21:30 ET
Incyte Provides Update on Parsaclisib and MCLA-145
2022-01-18 13:00 ET
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
2021-12-14 21:30 ET
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
2021-12-14 13:00 ET
Incyte to Present at Upcoming Investor Conferences
2021-12-11 14:00 ET
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
2021-11-09 13:30 ET
OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis
2021-11-09 13:00 ET
Incyte to Present at Upcoming Investor Conference
2021-11-04 14:07 ET
Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies
2021-11-04 13:00 ET
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
2021-11-02 11:00 ET
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2021-11-01 13:16 ET
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
2021-11-01 11:00 ET
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
2021-10-28 11:47 ET
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
2021-10-22 01:00 ET
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
2021-10-13 12:00 ET
Incyte to Report Third Quarter Financial Results
2021-10-02 09:15 ET
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
2021-09-30 09:56 ET
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
2021-09-28 21:00 ET
Incyte Names New Member to Its Board of Directors
2021-09-23 11:30 ET
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
2021-09-22 16:38 ET
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
2021-09-21 20:13 ET
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
2021-09-14 13:00 ET
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics
2021-09-13 20:30 ET
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
2021-08-17 14:26 ET
SEC Charges Biopharmaceutical Company Employee with Insider Trading
2021-08-17 12:00 ET
Incyte to Present at Upcoming Investor Conference
2021-08-16 23:00 ET
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
2021-08-03 11:00 ET
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2021-08-03 10:00 ET
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
2021-07-29 13:26 ET
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
2021-07-23 20:30 ET
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
2021-07-16 14:00 ET
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
2021-07-15 12:00 ET
Incyte to Report Second Quarter Financial Results
2021-07-14 21:00 ET
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
2021-06-24 19:30 ET
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
2021-06-12 21:01 ET
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
2021-06-11 11:30 ET
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
2021-06-08 11:30 ET
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
2021-06-01 23:30 ET
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses
2021-05-20 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2021-05-20 10:00 ET
Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting
2021-05-19 21:14 ET
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
2021-05-17 11:30 ET
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
2021-05-12 20:18 ET
Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
2021-05-04 11:00 ET
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2021-05-03 12:00 ET
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
2021-04-27 12:00 ET
Incyte to Present at Upcoming Investor Conference
2021-04-23 14:00 ET
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
2021-04-23 14:00 ET
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
2021-04-20 12:00 ET
Multiple Abstracts from Incyte’s Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
2021-04-20 10:45 ET
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
2021-04-13 12:00 ET
Incyte to Report First Quarter Financial Results
2021-04-08 10:45 ET
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
2021-04-06 20:30 ET
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
2021-03-29 16:04 ET
Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
2021-03-23 09:13 ET
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
2021-03-18 20:30 ET
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
2021-03-11 13:00 ET
Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021
2021-03-03 11:45 ET
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
2021-02-26 08:00 ET
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
2021-02-22 13:00 ET
Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease
2021-02-19 13:00 ET
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
2021-02-11 13:00 ET
Incyte to Present at Upcoming Investor Conference
2021-02-09 12:00 ET
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs
2021-01-29 18:36 ET
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
2021-01-21 21:30 ET
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
2021-01-19 13:00 ET
Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
2020-12-30 12:30 ET
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
2020-12-14 06:15 ET
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
2020-12-11 19:01 ET
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
2020-12-09 13:00 ET
Incyte to Present at Upcoming Investor Conference
2020-12-07 15:00 ET
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
2020-12-04 17:30 ET
Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi®) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
2020-11-19 22:20 ET
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
2020-11-12 13:00 ET
Incyte to Present at Upcoming Investor Conference
2020-11-09 13:00 ET
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer 2020 Annual Meeting
2020-11-05 12:00 ET
Incyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2020-11-04 20:55 ET
More than 40 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 62nd Annual ASH Virtual Meeting
2020-11-02 19:00 ET
ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis
2020-10-31 14:45 ET
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
2020-10-30 13:00 ET
Incyte Ranked Second Among Science Magazine’s 2020 Top Biopharma Employers
2020-10-30 10:45 ET
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
2020-10-29 12:00 ET
Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments
2020-10-20 12:00 ET
Incyte to Report Third Quarter Financial Results
2020-10-08 15:39 ET
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
2020-10-05 16:00 ET
Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
2020-09-18 11:44 ET
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
2020-09-18 10:00 ET
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal
2020-09-17 17:41 ET
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
2020-09-14 10:30 ET
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial
2020-09-09 14:05 ET
Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community
2020-09-02 21:04 ET
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
2020-09-01 12:00 ET
Incyte to Present at Upcoming Investor Conference
2020-08-04 11:00 ET
Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2020-07-23 11:15 ET
Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints
2020-07-16 12:00 ET
Incyte to Report Second Quarter Financial Results
2020-06-29 11:05 ET
Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14
2020-06-17 12:00 ET
Incyte Investor Conference Update
2020-06-15 12:00 ET
Incyte Launches New Global Responsibility Section on Incyte.com
2020-06-03 12:00 ET
Incyte to Present at Upcoming Investor Conferences
2020-05-29 12:00 ET
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
2020-05-21 12:00 ET
Incyte to Present at Upcoming Investor Conference
2020-05-14 16:18 ET
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings
2020-05-06 18:41 ET
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14
2020-05-05 11:00 ET
Incyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2020-04-29 12:00 ET
Incyte to Present at Upcoming Investor Conference
2020-04-24 12:00 ET
Incyte Appoints Christine Lennon as General Manager, Incyte Biosciences Canada
2020-04-22 21:01 ET
Incyte Announces Pivotal REACH2 Study Data Published in NEJM Highlight Superior Efficacy of Ruxolitinib (Jakafi®) versus Best Available Therapy in Patients with Acute Graft-Versus-Host Disease
2020-04-18 00:53 ET
 FDA Approves Incyte’s Pemazyre™ (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
2020-04-17 19:46 ET
Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
2020-04-16 12:00 ET
Incyte to Report First Quarter Financial Results
2020-04-05 12:00 ET
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
2020-04-02 21:05 ET
Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
2020-03-26 12:00 ET
Incyte Names New Member to Its Board of Directors
2020-03-24 11:30 ET
Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference
2020-02-27 14:00 ET
Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)
2020-02-19 14:00 ET
Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community
2020-02-19 12:30 ET
Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis
2020-02-13 12:00 ET
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
2020-02-11 13:00 ET
Incyte to Present at Upcoming Investor Conference
2020-02-11 06:17 ET
Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer
2020-01-28 12:30 ET
Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis
2020-01-23 13:00 ET
Incyte to Report Fourth Quarter and Year-End Financial Results
2020-01-07 11:00 ET
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
2020-01-02 21:30 ET
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
2019-12-19 12:30 ET
Incyte Names New Member to Its Board of Directors
2019-12-05 13:00 ET
Incyte to Present at Upcoming Investor Conference
2019-11-27 12:30 ET
Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
2019-11-25 13:00 ET
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting
2019-11-14 13:00 ET
Incyte to Present at Upcoming Investor Conference
2019-10-29 11:00 ET
Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2019-10-22 12:00 ET
Incyte to Present at Upcoming Investor Conference
2019-10-16 11:00 ET
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
2019-10-12 06:32 ET
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
2019-10-10 12:00 ET
Incyte to Report Third Quarter Financial Results
2019-10-08 10:45 ET
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
2019-09-27 12:00 ET
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
2019-09-25 11:30 ET
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
2019-09-23 11:30 ET
Incyte to Host Investor Conference Call from ESMO 2019
2019-08-23 18:55 ET
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
2019-04-11 12:00 ET
Incyte to Report First Quarter Financial Results
2019-04-02 18:58 ET
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
2019-02-28 15:30 ET
Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019
2019-02-28 13:00 ET
Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019
2019-01-29 12:25 ET
Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019

SEC forms

Show financial reports only

SEC form 10
2026-04-28 20:02 ET
Incyte published news for 2026 q1
SEC form 8
2026-04-28 11:03 ET
Incyte published news for 2026 q1
SEC form 8
2026-04-28 11:03 ET
Incyte published news for 2026 q1
SEC form 10
2026-02-10 21:01 ET
Incyte published news for 2025 q4
SEC form 8
2026-02-10 12:06 ET
Incyte published news for 2025 q4
SEC form 8
2026-02-10 12:06 ET
Incyte reported for 2025 q4
SEC form 10
2025-10-28 20:03 ET
Incyte reported for 2025 q3
SEC form 8
2025-10-28 11:04 ET
Incyte published news for 2025 q3
SEC form 8
2025-10-28 11:04 ET
Incyte reported for 2025 q3
SEC form 10
2025-07-29 20:01 ET
Incyte reported for 2025 q2
SEC form 8
2025-07-29 11:06 ET
Incyte published news for 2025 q2
SEC form 8
2025-07-29 11:06 ET
Incyte reported for 2025 q2
SEC form 10
2025-04-29 00:00 ET
Incyte published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Incyte published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
Incyte reported for 2025 q1
SEC form 10
2025-02-10 16:01 ET
Incyte published news for 2024 q4
SEC form 8
2025-02-10 07:02 ET
Incyte published news for 2024 q4
SEC form 8
2025-02-10 07:02 ET
Incyte reported for 2024 q4
SEC form 10
2025-02-10 00:00 ET
Incyte published news for 2024 q4
SEC form 10
2024-10-29 16:02 ET
Incyte reported for 2024 q3
SEC form 8
2024-10-29 07:05 ET
Incyte published news for 2024 q3
SEC form 8
2024-10-29 07:05 ET
Incyte reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Incyte reported for 2024 q3
SEC form 10
2024-07-30 16:10 ET
Incyte published news for 2024 q2
SEC form 8
2024-07-30 07:15 ET
Incyte published news for 2024 q2
SEC form 8
2024-07-30 07:15 ET
Incyte reported for 2024 q2
SEC form 10
2024-07-30 00:00 ET
Incyte published news for 2024 q2
SEC form 10
2024-04-30 16:02 ET
Incyte published news for 2024 q1
SEC form 8
2024-04-30 07:10 ET
Incyte published news for 2024 q1
SEC form 8
2024-04-30 07:10 ET
Incyte reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
Incyte published news for 2024 q1
SEC form 10
2024-02-13 00:00 ET
Incyte published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Incyte published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Incyte reported for 2023 q4
SEC form 10
2023-10-31 16:02 ET
Incyte published news for 2023 q3
SEC form 8
2023-10-31 07:05 ET
Incyte reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Incyte published news for 2023 q3
SEC form 10
2023-08-01 16:02 ET
Incyte published news for 2023 q2
SEC form 6
2023-08-01 07:05 ET
Incyte reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Incyte published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Incyte published news for 2023 q2
SEC form 6
2023-06-15 14:10 ET
Incyte published news for 2023 q1
SEC form 10
2023-05-02 00:00 ET
Incyte published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
Incyte reported for 2023 q1
SEC form 10
2023-02-07 16:02 ET
Incyte reported for 2022 q4
SEC form 6
2023-02-07 07:05 ET
Incyte published news for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Incyte reported for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Incyte reported for 2022 q4
SEC form 10
2022-11-01 16:06 ET
Incyte reported for 2022 q3
SEC form 6
2022-11-01 07:05 ET
Incyte published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Incyte reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Incyte reported for 2022 q3
SEC form 6
2022-10-05 16:03 ET
Incyte published news for 2022 q3
SEC form 6
2022-10-04 07:30 ET
Incyte published news for 2022 q3
SEC form 10
2022-08-02 16:03 ET
Incyte reported for 2022 q2
SEC form 6
2022-08-02 07:25 ET
Incyte published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Incyte reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Incyte reported for 2022 q2
SEC form 6
2022-06-16 16:01 ET
Incyte published news for 2022 q1
SEC form 10
2022-05-03 16:08 ET
Incyte reported for 2022 q1
SEC form 6
2022-05-03 07:16 ET
Incyte published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Incyte reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Incyte reported for 2022 q1
SEC form 6
2022-04-29 08:01 ET
Incyte published news for 2022 q1
SEC form 6
2022-04-21 08:21 ET
Incyte published news for 2022 q1
SEC form 10
2022-02-08 16:05 ET
Incyte published news for 2021 q4
SEC form 6
2022-02-08 07:17 ET
Incyte published news for 2021 q4
SEC form 10
2022-02-08 00:00 ET
Incyte published news for 2021 q4
SEC form 8
2022-02-08 00:00 ET
Incyte published news for 2021 q4
SEC form 6
2022-01-14 16:09 ET
Incyte published news for 2021 q4
SEC form 6
2022-01-05 16:13 ET
Incyte published news for 2021 q4
SEC form 6
2022-01-05 16:08 ET
Incyte published news for 2021 q4
SEC form 10
2021-11-02 17:05 ET
Incyte published news for 2021 q3
SEC form 6
2021-11-02 16:50 ET
Incyte published news for 2021 q3
SEC form 6
2021-11-02 07:15 ET
Incyte published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Incyte published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Incyte published news for 2021 q3
SEC form 6
2021-09-29 18:06 ET
Incyte published news for 2021 q2
SEC form 6
2021-09-28 16:48 ET
Incyte published news for 2021 q2
SEC form 6
2021-08-20 16:02 ET
Incyte published news for 2021 q2
SEC form 10
2021-08-03 16:03 ET
Incyte published news for 2021 q2
SEC form 6
2021-08-03 07:15 ET
Incyte published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Incyte published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 18:39 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:44 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:39 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:34 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:28 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:23 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-07 16:14 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-02 19:15 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-02 07:32 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-02 07:23 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-02 07:19 ET
Incyte published news for 2021 q2
SEC form 6
2021-07-02 07:16 ET
Incyte published news for 2021 q2
SEC form 6
2021-06-30 16:14 ET
Incyte published news for 2021 q1
SEC form 6
2021-06-30 16:11 ET
Incyte published news for 2021 q1
SEC form 6
2021-05-27 16:06 ET
Incyte published news for 2021 q1
SEC form 10
2021-05-04 16:10 ET
Incyte published news for 2021 q1
SEC form 6
2021-05-04 07:08 ET
Incyte published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Incyte published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Incyte published news for 2021 q1
SEC form 6
2021-04-16 08:15 ET
Incyte published news for 2021 q1
SEC form 6
2021-02-19 07:01 ET
Incyte published news for 2020 q4
SEC form 10
2021-02-09 16:05 ET
Incyte published news for 2020 q4
SEC form 6
2021-02-09 07:11 ET
Incyte published news for 2020 q4
SEC form 10
2020-11-05 16:03 ET
Incyte published news for 2020 q3
SEC form 6
2020-11-05 07:08 ET
Incyte published news for 2020 q3